+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of treatment response for breast cancer: are we entering the era of "biological complete remission"?



Evaluation of treatment response for breast cancer: are we entering the era of "biological complete remission"?



Chinese Journal of Cancer Research 24(4): 403-407



Breast cancer is one of the most common malignancies in women. The post-operative recurrence and metastasis are the leading causes of breast cancer-related mortality. In this study, we tried to explore the role of circulating tumor cell (CTC) detection combination PET/CT technology evaluating the prognosis and treatment response of patients with breast cancer; meanwhile, we attempted to assess the concept of "biological complete remission" (bCR) in this regard. A 56-year-old patient with breast cancer (T(2)N(1)M(1), stage IV left breast cancer, with metastasis to axillary lymph nodes and lungs) received 6 cycles of salvage treatment with albumin-bound paclitaxel plus capecitabine and trastuzumab. Then, she underwent CTC detection and PET/CT for efficacy evaluation. CTC detection combination PET/CT is useful for the evaluation of the biological efficacy of therapies for breast cancer. The bCR of the patient appeared earlier than the conventional clinical imaging complete remission and promised the histological (pathological) complete remission. The integrated application of the concepts including bCR, imageological CR, and histological CR can achieve the early and accurate assessment of biological therapeutic reponse and prognosis of breast cancer.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053089346

Download citation: RISBibTeXText

PMID: 23359646


Related references

Treatment response evaluation by MRI in breast cancer patients receiving neoadjuvant chemotherapy: there is more than just pathologic complete response prediction. Breast Cancer Research and Treatment 136(1): 313-314, 2012

Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. Japanese Journal of Clinical Oncology 28(6): 368-373, 1998

Remission and survival data of metastatic breast cancer patients achieving complete remission with combination chemo immuno therapy. Clinical Research 26(3): 438A, 1978

Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission. Medical Oncology 29(3): 1477-1478, 2012

A 94 year old male stage IV breast cancer patient showing complete remission under tamoxifen treatment after operation. Journal of Surgical Oncology 51(1): 71-73, 1992

Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. A retrospective analysis. Oncology 44(1): 51-59, 1987

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Reports in Oncology 3(2): 131-136, 2010

Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases. Journal of Oncology Pharmacy Practice 20(2): 141-145, 2014

The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. International Journal of Biological Markers 13(1): 10-15, 1998

Locoregional recurrence of HER2-positive breast cancer - treatment after complete remission and long-term clinical benefits. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1924-1926, 2014

The significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease during therapy monitoring. Anticancer Research 18(6C): 4856, 1998

Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy. European Radiology 26(5): 1474-1484, 2016

A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer. World Journal of Surgical Oncology 9: 146, 2011

NEW ASPECTS REGARDING NEOADJUVANT RADIOCHEMOTHERAPY IN LOCALLY ADVANCED NONINFLAMMATORY BREAST CANCER AND PREDICTIVE FACTORS FOR A PATHOLOGIC COMPLETE REMISSION: IGCS-0016 Breast Cancer. International Journal of Gynecological Cancer 25(Suppl. 1): 1, 2015

Paclitaxel, carboplatin and trastuzumab (TCH) achieves high pathological complete remission rate after in vivo response directed 2-4 cycles of doxorubicin and cyclophosphamide (AC) in breast cancer patients. Journal of Clinical Oncology 24(18_Suppl): 10583-10583, 2016